| 0.08405 0.004 (5.33%) | 04-19 15:56 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.1 | 1-year : | 0.12 |
| Resists | First : | 0.09 | Second : | 0.1 |
| Pivot price | 0.08 |
|||
| Supports | First : | 0.07 | Second : | 0.05 |
| MAs | MA(5) : | 0.08 |
MA(20) : | 0.08  |
| MA(100) : | 0.11 |
MA(250) : | 0.39 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 54.5 |
D(3) : | 47.1 |
| RSI | RSI(14): 50.1 |
|||
| 52-week | High : | 1.25 | Low : | 0.06 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ NMRD ] has closed below upper band by 49.4%. Bollinger Bands are 49.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 60 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.09 - 0.09 | 0.09 - 0.09 |
| Low: | 0.07 - 0.07 | 0.07 - 0.07 |
| Close: | 0.08 - 0.08 | 0.08 - 0.08 |
Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Wed, 10 Apr 2024
Nemaura Medical Restructures Finances, Board Members Change - TipRanks.com - TipRanks
Wed, 03 Jan 2024
Nasdaq Down Over 100 Points; Sidus Space Shares Spike Higher - Esperion Therapeutics (NASDAQ:ESPR), Nemau - Benzinga
Wed, 13 Dec 2023
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision - Yahoo Finance
Mon, 04 Dec 2023
“Buzz on the Street” Show: Nemaura Medical (NASDAQ: NMRD) Update on Nasdaq Compliance Status | FINANCIAL ... - Financialbuzz.com
Tue, 21 Nov 2023
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth - Yahoo Finance
Mon, 13 Nov 2023
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 29 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 48.6 (%) |
| Held by Institutions | 4.4 (%) |
| Shares Short | 53 (K) |
| Shares Short P.Month | 192 (K) |
| EPS | -0.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.63 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -81.2 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.22 |
| PEG Ratio | 0 |
| Price to Book value | -0.14 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|